Cargando…
Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature
BACKGROUND: Medicinal products that have been developed and approved for one disease may be the object of additional clinical development in other disease areas or of additional pharmaceutical development for new and different formulations. The newly developed products can be named as repositioned o...
Autores principales: | Murteira, Susana, Ghezaiel, Zied, Karray, Slim, Lamure, Michel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Co-Action Publishing
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865745/ https://www.ncbi.nlm.nih.gov/pubmed/27226826 http://dx.doi.org/10.3402/jmahp.v1i0.21131 |
Ejemplares similares
-
Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications
por: Murteira, Susana, et al.
Publicado: (2014) -
Drug repurposing in pharmaceutical industry and its impact on market access: market access implications
por: Murteira, Susana, et al.
Publicado: (2014) -
A reassessment of the nomenclature of polychlorinated biphenyl (PCB) metabolites.
por: Maervoet, Johan, et al.
Publicado: (2004) -
New drug regulations in France: what are the impacts on market access? Part 2 – impacts on market access and impacts for the pharmaceutical industry
por: Rémuzat, Cécile, et al.
Publicado: (2013) -
Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
por: Badora, Karolina, et al.
Publicado: (2017)